AEON

AEON Biopharma, Inc. (AEON) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. AEON Biopharma, Inc. is a pre-revenue biopharmaceutical company developing ABP-450, a botulinum toxin complex intended as a biosimilar to Botox® for therapeutic indications. The company operates as a single segment focused on research and development (R&D) and regulatory advancement under the Section 351(k) biosimilar pathway. As of March 31, 2026, the company held $6.2 million in cash and cash equivalents.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss vs. Income: The company reported a net loss of $11.8 million in Q1 2026, compared to net income of $9.1 million in Q1 2025. The prior year income was driven by a non-cash gain of $86.7 million from the change in fair value of warrants, which was absent in the current period.
• Operating Expenses: Total operating costs increased to $5.9 million from $0.5 million. This was driven by a rise in R&D expenses to $2.0 million (from $0.8 million) and SG&A to $3.9 million (from $3.1 million), reflecting increased payroll, bonuses, and consulting fees.
• Debt Restructuring: The company exchanged $15.0 million in existing convertible notes held by Daewoong for common stock, pre-funded warrants, a new $1.5 million convertible note, and warrants. This reduced the convertible note liability on the balance sheet from $34.6 million (Dec 2025) to $1.5 million (Mar 2026).
• Financing Activity: The company raised $6.0 million in gross proceeds via a PIPE financing (closed in two tranches) and $1.7 million via an At-The-Market (ATM) offering during the quarter.

Outlook, Risks, and Management Commentary

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. The company expects to have sufficient cash to fund operations only into the third quarter of 2026 without additional financing.
• Regulatory Progress: In January 2026, the FDA held a BPD Type 2a meeting. The FDA acknowledged scientific challenges but noted the company's analytical methodologies appeared reasonable. The company plans to complete the majority of its analytical comparability program in 2026 and request a BPD Type 2b meeting later in the year.
• Listing Compliance: The company received notices of non-compliance from NYSE American regarding stockholders' equity requirements (deficit of ~$55 million). The company has an approved plan to regain compliance by August 3, 2026, or it faces potential delisting.
• Legal Proceedings: A lawsuit filed by Aegis Capital Corp. regarding a right of first refusal was dismissed with prejudice in April 2026.
• Capital Needs: Further development and commercialization of ABP-450 require significant additional funding. Future equity financing will likely result in substantial dilution to existing shareholders.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to secure financing before Q3 2026 to avoid operational cessation.
• Listing Status: Monitor progress toward regaining NYSE American compliance by the August 3, 2026 deadline.
• Dilution Risk: Assess the impact of outstanding warrants (PIPE, Daewoong, Series A/B) and pre-funded warrants on future share count and value.
• FDA Milestones: Track the timing and outcome of the planned BPD Type 2b meeting and the submission of the Biologics License Application (BLA).
• Debt Covenants: Review the terms of the new $1.5 million Daewoong convertible note, including conversion triggers and security interests on company assets.